Coeptis Therapeutics Holdings, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
ZSQR$2.30-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
| As of | ||
|---|---|---|
| September 30, 2025 (unaudited) | December 31, 2024 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $4,908,487 | $532,885 |
| Accounts receivable | 82,500 | – |
| Marketable securities | 421,698 | – |
| Interest receivable | 3,541 | – |
| Prepaid assets | 574,636 | 518,407 |
| TOTAL CURRENT ASSETS | 5,990,862 | 1,051,292 |
| PROPERTY AND EQUIPMENT | ||
| Furniture and fixtures | 25,237 | 25,237 |
| Less: accumulated depreciation | 15,217 | 14,777 |
| Furniture and fixtures, net | 10,020 | 10,460 |
| OTHER ASSETS | ||
| Investments | 6,941,082 | 5,691,084 |
| Intangible assets, net | 406,406 | 541,875 |
| Co-development rights, net | 804,167 | 1,554,166 |
| Right of use asset, net of accumulated amortization | 29,104 | 59,783 |
| Total other assets | 8,180,759 | 7,846,908 |
| TOTAL ASSETS | $14,181,641 | $8,908,660 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $783,103 | $1,269,763 |
| Accrued expenses | 210,892 | 736,884 |
| Convertible notes payable, net of debt discount of $0 and $435,635 | – | 1,087,873 |
| Notes payable, current portion, in default | 100,000 | 100,000 |
| Right of use liability, current portion | 29,865 | 42,305 |
| Customer deposit | 1,461,504 | – |
| Derivative liability | – | 1,041,484 |
| Other current liabilities | 120,000 | 235,000 |
| TOTAL CURRENT LIABILITIES | 2,705,364 | 4,513,309 |
| LONG TERM LIABILITIES | ||
| SBA loan payable | 150,000 | 150,000 |
| Derivative liability warrants | 409,500 | 359,250 |
| Right of use liability, non-current portion | – | 18,875 |
| TOTAL LONG TERM LIABILITIES | 559,500 | 528,125 |
| TOTAL LIABILITIES | 3,264,864 | 5,041,434 |
| COMMITMENTS AND CONTINGENCIES (NOTE 11) | – | – |
| STOCKHOLDERS' EQUITY | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 and 6,520 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | – | 2 |
| Common stock, $0.0001 par value, 150,000,000 shares authorized, 5,157,611 and 2,116,191 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 516 | 212 |
| Additional paid-in capital | 120,841,292 | 102,976,748 |
| Common stock subscribed | – | 541,875 |
| Subscription receivable | (2,100,368) | (2,100,000) |
| Accumulated deficit | (108,375,858) | (98,036,713) |
| TOTAL STOCKHOLDERS' EQUITY - CONTROLLING INTERESTS | 10,365,582 | 3,382,124 |
| TOTAL STOCKHOLDERS' EQUITY - NONCONTROLLING INTERESTS | 551,195 | 485,102 |
| TOTAL STOCKHOLDERS' EQUITY | 10,916,777 | 3,867,226 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $14,181,641 | $8,908,660 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.